mPEG-PLGA from PolySciTech used in development of combination chemotherapy nanoparticles for treatment of lung cancer
Lung cancer is a prevalent and deadly disease
contributing to about 222,500 new cases and 155,870 deaths per year in America
alone. Lung cancer propagates itself through cancer stem-cells, cells within
cancer which can differentiate into multiple cell types. Treating the cancer
requires both eliminating the mature cancer cells and the stem-cells, so that
the cancer cannot grow back. Recently, researchers at Xiangyang Central
Hospital and Second Military Medical University (China) used mPEG-PLGA
(PolyVivo AK101) from PolySciTech (www.polyscitech.com)
to generate salinomycin and gefitinib loaded nanoparticles for lung cancer
treatment. This research holds promise to develop more effective treatment
strategies for this disease by eliminating both cancer cells and cancer stem
cells. Read more: Zhang, Yu, Qi Zhang, Jing Sun, Huijie Liu, and Qingfeng Li. "The
combination therapy of salinomycin and gefitinib using poly (D,
L-lactic-co-glycolic acid)-poly (ethylene glycol) nanoparticles for targeting
both lung cancer stem cells and cancer cells." OncoTargets and therapy 10
(2017): 5653. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709995/
“Abstract: Purpose: Lung
cancer (LC) is the leading cause of cancer death worldwide. Evidences suggest
that both LC cancer stem cells (CSCs) and cancer cells are supposed to be
eliminated to achieve superior treatment effect against LC. Salinomycin could
eradiate CSCs in various types of cancers, and gefitinib is a first-line
therapy in LC. The purpose of the present study was to develop salinomycin-loaded
nanoparticles (salinomycin-NPs) combined with gefitinib-loaded nanoparticles
(gefitinib-NPs) to eradicate both LC CSCs and cancer cells. Methods: Salinomycin
and gefitinib were encapsulated separately by poly(d,l-lactic-co-glycolic
acid)-poly(ethylene glycol) nanoparticles by the emulsion/solvent evaporation
approach. The anti-LC activity of salinomycin-NPs and gefitinib-NPs was
investigated. Results: Salinomycin-NPs and gefitinib-NPs are of ~140 nm in
size, high drug encapsulation efficacy and sustained release of drugs. CD133+
LC CSCs showed the characteristics of CSCs, including significantly enhanced
stem cell gene expression, tumorsphere formation ability, and tumorigenicity in
mice. Both salinomycin and salinomycin-NPs are capable of selectively inhibiting
LC CSCs, as reflected by their enhanced cytotoxic effects toward CD133+ LC CSCs
and ability to reduce tumorsphere formation in LC cell lines, whereas gefitinib
and gefitinib-NPs could significantly inhibit LC cells. Salinomycin-NPs and
salinomycin could reduce the population of LC CSCs in the tumors in vivo. It is
noteworthy that salinomycin-NPs combined with gefitinib-NPs inhibited the
growth of tumors more efficiently compared with salinomycin combined with
gefitinib or single salinomycin-NPs or gefitinib-NPs. Conclusion: Salinomycin-NPs
combined with gefitinib-NPs represent a potential approach for LC by inhibiting
both LC CSCs and cancer cells. Keywords: cancer stem cells, lung cancer,
nanoparticles, salinomycin, gefitinib”
No comments:
Post a Comment